×
About 1,603 results

ALLMedicine™ Adrenocortical Carcinoma Center

Research & Reviews  605 results

Identification of oncological characteristics associated with improved overall survival...
https://doi.org/10.1016/j.urolonc.2021.06.019
Urologic Oncology; Ginsburg KB, Chandra AA et. al.

Jul 25th, 2021 - To test for an association between oncological risk factors and overall survival in patients with non-metastatic adrenocortical carcinoma treated with adjuvant radiation therapy at high-risk for recurrence per NCCN guidelines. We analyzed data fro...

The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.
https://doi.org/10.1007/s13318-021-00700-5 10.1124/pr.112.005660 10.3390/pharmaceutics11030129 10.1016/j.apsb.2015.07.003 10.1517/17425247.4.4.403 10.1016/j.ejps.2006.04.016 10.1210/er.2013-1029 10.3733/hilg.v42n10p383 10.3389/fgene.2019.00821 10.14740/jocmr3503w 10.1093/annonc/mds231 10.1016/j.ejca.2013.02.034 10.1200/JCO.2008.17.2775 10.1016/j.beem.2008.10.008 10.1530/EJE-18-0608 10.1007/s12020-019-02033-5 10.1371/journal.pone.0103744 10.1016/j.jamcollsurg.2018.01.051 10.1038/ng.2953 10.1016/j.ccell.2016.04.002 10.1530/EC-18-0526 10.1677/erc.1.01029 10.1056/NEJMoa1200966 10.1038/nrendo.2010.235 10.1016/j.humpath.2014.11.015 10.1210/endo-62-3-334 10.1210/endo-62-3-326 10.3390/pharmaceutics11110566 10.1016/j.jamcollsurg.2015.12.013 10.1210/jc.2016-2894 10.1111/j.1365-2125.2006.02579.x 10.1111/j.1365-2125.2009.03369.x 10.1007/s40618-013-0049-2 10.1016/j.coemr.2019.08.010 10.2217/pgs.12.116 10.1677/ERC-07-0003 10.1210/jcem-36-4-730 10.1530/ERC-12-0217 10.3892/mmr.2012.1244 10.1530/ERC-13-0150 10.1210/en.2015-1367 10.1055/s-0034-1372036 10.1210/clinem/dgaa293 10.1210/en.2015-1796 10.3390/cancers12010247 10.17925/EE.2018.14.2.62 10.1016/j.beem.2020.101415 10.1007/BF00258213 10.1007/s00280-007-0468-x 10.1016/0009-2797(89)90063-X 10.1002/jps.2600840203 10.1002/bmc.2696 10.1289/ehp.6141 10.1530/EJE-15-0946 10.3390/life11030266 10.1080/10826076.2015.1057645 10.1016/j.jchromb.2011.06.001 10.3109/00498250903470230 10.1007/BF00685956 10.1016/0041-008X(85)90266-2 10.1210/JC.2015-2080 10.1007/s12672-014-0189-7 10.1097/FTD.0000000000000102 10.1530/EJE-18-0342 10.1007/s12020-014-0517-2 10.3109/03602532.2012.743560 10.1016/S0034-5288(18)30766-5 10.1210/jc.2010-2676 10.1530/EJE-13-0242 10.1210/jc.2017-02591 10.1124/dmd.30.2.113 10.1530/EJE-10-0956 10.1530/EJE-18-0342 10.1038/bjc.1994.183 10.1210/jc.2013-2281 10.3390/cancers12030740 10.1111/j.1365-2265.2005.02403.x 10.1155/2013/624962 10.1634/theoncologist.2017-0426 10.1297/cpe.17.71 10.1111/cen.12868 10.1007/s00216-019-01868-1 10.1007/s11095-008-9637-9 10.1007/BF00265384 10.1016/j.colsurfb.2011.03.015 10.3109/03639040903225083 10.1016/S0168-3659(01)00432-1 10.2174/092986712804143376 10.1016/j.chemosphere.2009.03.050 10.1080/01496395.2011.617805 10.3109/10837450.2011.614250 10.1166/jcsb.2013.1044 10.1016/j.pharma.2013.02.001 10.1080/10837450.2020.1762645 10.1007/978-3-319-42609-9_6 10.1016/j.ejps.2015.12.008 10.1016/j.biomaterials.2018.05.022 10.1002/mabi.201900178 10.1016/j.jconrel.2019.04.014 10.1021/acs.biomac.9b00618 10.1021/acs.biomac.8b00708 10.1021/jacs.7b05376 10.1002/pat.3556 10.1021/acs.molpharmaceut.9b01117 10.1016/j.biomaterials.2010.02.057 10.1016/j.jconrel.2015.02.024 10.1021/acsnano.7b07878 10.1016/j.nano.2020.102345 10.1016/j.jconrel.2011.04.010 10.1016/j.biomaterials.2016.06.002 10.1634/theoncologist.2016-0459 10.1097/CCO.0000000000000695 10.1016/j.beem.2020.101434 10.1016/j.ando.2020.12.003 10.21037/amj.2020.01.07 10.1007/s12672-014-0182-1 10.1016/S1470-2045(15)70081-1 10.1530/EJE-09-0804 10.1210/jc.2012-1419 10.1055/a-0747-5571 10.1210/jc.2013-2298 10.1210/clinem/dgz318 10.1530/ERC-13-0439 10.1530/JOE-11-0427 10.1530/ERC-16-0249 10.1016/j.biomaterials.2018.10.032
European Journal of Drug Metabolism and Pharmacokinetics; Haider MS, Ahmad T et. al.

Jul 22nd, 2021 - Adrenocortical carcinoma (ACC) is a malignant tumor originating from the adrenal gland cortex with a heterogeneous but overall dismal prognosis in advanced stages. For more than 50 years, mitotane has remained a cornerstone for the treatment of AC...

Application of an in Vitro Assay to Identify Chemicals That Increase Estradiol and Prog...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293912
Environmental Health Perspectives; Cardona B, Rudel RA

Jul 22nd, 2021 - Established breast cancer risk factors, such as hormone replacement therapy and reproductive history, are thought to act by increasing estrogen and progesterone (P4) activity. We aimed to use in vitro screening data to identify chemicals that incr...

Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor mi...
https://doi.org/10.1016/j.surg.2021.04.045
Surgery Baechle JJ, Hanna DN et. al.

Jul 16th, 2021 - Immunotherapeutic response failure of adrenocortical carcinomas highlights a need for novel strategies targeting immune cell populations in the tumor microenvironment to overcome tumor resistance and enhance therapeutic response. A recent study ex...

Three Dimensional Cell Culturing for Modeling Adrenal and Pituitary Tumors.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262162
Pathology Oncology Research : POR; Krokker L, Szabó B et. al.

Jul 15th, 2021 - In vitro monolayer conditions are not able to reproduce the complexity of solid tumors, still, there is scarce information about the 3D cell culture models of endocrine tumor types. Therefore, our aim was to develop in vitro 3D tumor models by dif...

see more →

Guidelines  1 results

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an end...
https://doi.org/10.1210/jc.2008-0104
The Journal of Clinical Endocrinology and Metabolism; Funder JW, Carey RM et. al.

Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...

see more →

Clinicaltrials.gov  18 results

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03370718

May 4th, 2020 - PRIMARY OBJECTIVES: I. To estimate progression free survival at 4 months. SECONDARY OBJECTIVES: I. Best overall response rate. II. Overall survival (OS). III. Toxicity assessment by the Common Terminology Criteria for Adverse Events (CTCAE) versio...

Sunitinib in Refractory Adrenocortical Carcinoma
https://clinicaltrials.gov/ct2/show/NCT00453895

Jan 31st, 2019 - Although a first randomized trial in patients with advanced ACC leading to the establishment of a first line cytotoxic chemotherapy is ongoing (FIRM-ACT), the failure rate even of this FIRM-ACT study is most likely clearly above 50%. Therefore, th...

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
https://clinicaltrials.gov/ct2/show/NCT01262235

Jan 16th, 2019 - This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid tumors or lymphom...

Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma
https://clinicaltrials.gov/ct2/show/NCT03723941

Oct 30th, 2018 - Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with an annual rate of 0.5.2 cases per million population. Despite complete resection of early-stage disease recurrence rates in ACC are very high (60%.70%). Patients with Ki67 ≥ 10% ar...

A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
https://clinicaltrials.gov/ct2/show/NCT00924989

Sep 5th, 2018 - Patients will be randomized 2:1 to receive either single agent OSI-906 (Arm A) or placebo (Arm B) and will be stratified according to prior systemic cytotoxic chemotherapy for ACC, and Eastern Cooperative Oncology Group (ECOG) performance status, ...

see more →

News  16 results

Urine Screen as Part of Triple Test Improves ID of Adrenal Cancer
https://www.medscape.com/viewarticle/934790

Jul 29th, 2020 - A strategy that includes a urine steroid test along with imaging characteristics and tumor size criteria can significantly improve the challenging diagnosis of adrenocortical cancer, helping to avoid unnecessary, and often unsuccessful, further im...

Adrenocortical Carcinoma Clinical Practice Guidelines (2018)
https://reference.medscape.com/viewarticle/904250

Nov 5th, 2018 - Clinical practice guidelines for the management of adrenocortical carcinoma in adults were released in October 2018 by the European Society of Endocrinology.[1] Diagnosis Perform a detailed hormonal workup of all patients with suspected adrenocort...

Adrenocortical Carcinoma Clinical Practice Guidelines (2018)
https://reference.staging.medscape.com/viewarticle/904250

Nov 5th, 2018 - Clinical practice guidelines for the management of adrenocortical carcinoma in adults were released in October 2018 by the European Society of Endocrinology.[1] Diagnosis Perform a detailed hormonal workup of all patients with suspected adrenocort...

New Clinical Practice Guidelines, August 2018 Edition
https://www.medscape.com/viewarticle/900291_6

Aug 9th, 2018 - Oncology Adrenocortical Carcinoma Advanced Breast Cancer Cancer Pain Management Constipation in Advanced Cancer HER2+ Advanced Breast Cancer

Resection of recurrence shows survival benefit for adrenocortical carcinoma
https://www.mdedge.com/internalmedicine/article/109105/pituitary-thyroid-adrenal-disorders/resection-recurrence-shows
Richard Mark Kirkner

May 25th, 2016 - BALTIMORE – Patients who have recurrent adrenocortical carcinoma appear to have one option to increase their survival: surgery that includes complete tumor resection – but it may a viable path only if the recurrence occurred a year or more after t.

see more →

Patient Education  1 results see all →